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Abstract: The use of spinal cord stimulation (SCS) devices to treat chronic, refractory neuro-
pathic pain continues to expand in application. While device-related complications have been 
well described, inflammatory reactions to the components of these devices remain underreported. 
In contrast, hypersensitivity reactions associated with other implanted therapies, such as endo-
vascular and cardiac rhythm devices, have been detailed. The purpose of this case series is to 
describe the clinical presentation and course of inflammatory reactions as well as the histology of 
these reactions. All patients required removal of the entire device after developing inflammatory 
reactions over a time course of 1–3 months. Two patients developed a foreign body reaction in 
the lead insertion wound as well as at the implantable pulse generator site, with histology positive 
for giant cells. One patient developed an inflammatory dermatitis on the flank and abdomen that 
resolved with topical hydrocortisone. “In vivo” testing with a lead extension fragment placed 
in the buttock resulted in a negative reaction followed by successful reimplantation of an SCS 
device. Inflammatory reactions to SCS devices can manifest as contact dermatitis, granuloma 
formation, or foreign body reactions with giant cell formation. Tissue diagnosis is essential, 
and is helpful to differentiate an inflammatory reaction from infection. The role of skin patch 
testing for 96 hours may not be suited to detect inflammatory giant cell reactions that manifest 
several weeks post implantation.
Keywords: spinal cord stimulation, delayed inflammatory responses, foreign body giant cell 
reactions, contact dermatitis
Introduction
Spinal cord stimulation (SCS) has been used since the 1960s to treat chronic refractory 
pain conditions. In particular, SCS has been extensively used to manage the painful 
symptoms related to chronic lumbosacral radiculopathy following failed back surgery 
syndrome and complex regional pain syndromes. Randomized controlled trials of 
SCS for failed back surgery syndrome have reported favorable long-term results.1,2 
Concurrently, there has been significant technologic advancement in the equipment for 
SCS. Specifically, implanting physicians can offer patients rechargeable implantable 
pulse generators, improved anchoring systems, and more stimulating lead contacts 
to ensure coverage for paresthesia in painful somatic regions. Thus, there is more 
widespread use of SCS therapy and acceptance among treating physicians.
Despite the positive findings and increasing experience of implanting physicians 
using SCS therapy, complications remain a common occurrence. An analysis of the 
available literature by Turner et al found that just over one third of patients have a 
complication.3 Prospective data from a multicenter evaluation of SCS for failed back 
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surgery syndrome showed a similar rate of complications, 
even in the hands of experienced implanters.4 These adverse 
events are usually lead migration, infection, lead breakage, 
and unwanted stimulation.4,5 An allergic or immunologic/
inflammatory reaction to the system components is thought 
to be rare, and has been estimated by Cameron to be 0.1%.5 
However, the true incidence may be underestimated because 
clinicians may fail to include it in the differential diagnosis, 
attributing an inflammatory reaction of the soft tissue sur-
rounding SCS components to infection. In addition, only 
two articles detail the cutaneous reaction to the components 
of SCS systems.6,7 The purpose of this paper is to detail the 
presentation, clinical course, and histologic findings in three 
patients with cutaneous reactions to spinal cord stimulator 
equipment components.
Case 1
The patient was a 61-year-old male who, despite two previous 
laminectomies, epidural injections, and multimodal analgesia 
(oxycodone/acetaminophen, cyclobenzaprine, ibuprofen), 
complained of severe pain secondary to left-sided chronic 
lumbosacral radiculopathy. The pain was 9/10 in intensity, 
located at his lower back on the left side with radiation down 
his posterior thigh, behind his knee to his lateral leg, and to 
the bottom of the sole of his foot. He had a past medical his-
tory of irritable bowel syndrome, squamous cell carcinoma of 
the skin, gastroesophageal reflux disease, and depression. The 
only reported allergy was to meperidine. Magnetic resonance 
imaging revealed no evidence of spinal stenosis, foraminal 
narrowing, or nerve root displacement, so he was implanted 
with an SCS consisting of two eight-contact leads, two lead 
extensions, and a rechargeable implantable pulse generator 
(EON™, St Jude Medical Neuromodulation Division, Plano, 
TX, USA) following a successful trial of 7 days.
He was seen one week after the operation and his wounds, 
which included the abdomen for the generator, flank for 
the extension, and back for lead insertion and anchoring, 
were noted to be dry with intact incisions, and no erythema, 
drainage, or tenderness. He was afebrile. At one month 
post operation, the patient developed a left-sided rash on 
his flank and abdomen, with no fevers or chills (Figure 1). 
The stimulator was working well, providing up to 60% pain 
relief. The incisions over his abdomen, flank, and back were 
well healed. However, he had an area of erythema/dermatitis 
that seemed to be localized to the area over the length of the 
lead extensions connecting the implantable pulse generator 
to the leads. The reaction did not involve the implantable 
pulse generator site. It was noted that this rash appeared to 
be an area of reactive inflammation, as opposed to infection, 
and he was diagnosed with a hypersensitivity reaction to the 
implanted wires. He was given topical 1% hydrocortisone 
cream and seen 7 days later, with resolution of the rash.
Forty-three days after implantation, the patient presented 
with complaints concerning wound drainage. There was no 
history of fall or trauma. The abdominal and flank incisions 
had dehisced, with device exposure and were draining pink, 
clear fluid. He was afebrile, with only mild tenderness of 
the wounds. His white blood cell count was 6.8 and the 
differential was abnormal for eosinophils at 5.4%, with no 
bandemia or elevation in fraction of neutrophils. Because 
of concerns for potential early infection, urgent explanta-
tion of the entire SCS device was performed. Exploration 
of the wounds did not reveal any purulent material, but the 
subcutaneous tissue directly involving the wound was frail, 
bled easily with manipulation, and was difficult to coagulate. 
A tissue biopsy was taken from the lead extension site 
(Figure 2). Once cultures were sent, the patient was started 
on empiric vancomycin and ceftazidime.
Wound cultures were positive for rare coagulase negative 
Staphylococci as well as rare Staphylococcus aureus, and the 
patient was treated for 2 weeks with intravenous vancomycin. 
Clinically, however, he did not manifest with the usual clini-
cal findings suggestive of device infection. One month later, 
all incisions were well healed. Because the initial reaction to 
the SCS equipment involved the flank to the abdomen but 
not the back, the buttock was targeted as a potential site for 
the implantable pulse generator. In an attempt to rule out a 
hypersensitivity reaction, an in vivo allergy test using a por-
tion of the extension lead was done (Figure 3). A 4 cm lead 
extension piece was placed in the left buttock via a 12 gauge 
Figure 1 Erythematous rash on the abdomen and flank (case 1) primarily overlying 
the lead extensions.
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angiocatheter upon removal of the introducer. The extension 
fragment was placed into the catheter which was removed 
leaving the lead in the subcutaneous tissue. The puncture 
site was closed with 4.0 Monocryl™ suture (Ethicon Inc, 
Somerville, NJ, USA). After a 2-month follow-up period, 
there was no cutaneous reaction to the lead extension.
One month later, the system was reimplanted, with the pulse 
generator pocket site now in the left buttock. The patient toler-
ated the procedure well and had no postoperative complications. 
Now three years following reimplantation, his pain is well 
managed with a combination of SCS and medications.
Case 2
The patient was a 44-year-old gentleman with a past surgi-
cal history of decompression laminotomy, discectomy, and 
fusion at L5/S1. One year following the surgery, the patient 
continued to have worsening low back pain, with radiation 
down his lateral calf into the lateral aspect of his dorsal foot. 
The patient described the pain as being 8/10 in severity, with 
an achy quality that was partially alleviated with oxycodone/
acetaminophen. He had a past history of depression and 
colitis, and had no known drug allergies. Magnetic reso-
nance imaging had revealed prior posterior decompression 
of posterior fusion at the L5/S1 level with metallic hardware 
artifacts with grade 1 anterolisthesis with posterior uncover-
ing of the disc and superimposed left paracentral protrusion. 
There was also enhancing tissue encasing the thecal sac and 
the S1 nerve roots at the L5–S1 level.
The patient had no sustained improvement with trans-
foraminal epidural injections. Following a one-week trial 
of SCS, he reported excellent relief and was subsequently 
implanted with dual eight-contact leads and the implant-
able EON™ pulse generator was placed in the left buttock 
region. After two weeks, the patient complained of increased 
pain from the mid back incision. On physical examination, 
there was trace serosanguinous drainage, without significant 
erythema or pus. He was afebrile but had a white blood cell 
count of 14.6. The differential revealed 83.9% neutrophils 
and 12.4% lymphocytes, with no bands. The patient was 
treated for a presumptive superficial wound infection with 
antibiotics for ten days with resolution of the pain and white 
count.
However, despite resolution of the infection, the patient 
still had a skin inflammatory change that persisted for 
5 weeks following implantation (Figure 4). Because of poor 
Figure 2 Histopathology of soft tissue removed from the lead extension wound at 
the flank (case 1). Light microscopy revealed granulation tissue, necrotic debris, and 
fibrin with acute and chronic inflammation. No giant cell reaction was seen.
Figure 3 The distal 4 cm of the lead extension pictured above was inserted via a 
12 gauge angiocatheter into the subcutaneous tissue of the left buttock in case 1 
for in vivo testing.
Figure 4 Persistent inflammatory reaction on the upper back (L2 level) 5 weeks 
post implantation in case 2. Lead strain relief is directly under the inflammatory 
tissue.
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wound healing, the decision was made to remove the dual 
leads, silastic anchors with associated 0 silk sutures, and the 
implantable pulse generator. Intraoperative frozen sections 
revealed acute and chronic inflammation, with a foreign body 
giant cell reaction (Figure 5A and B). The removal of the 
soft inflammatory tissue in Figure 4 revealed the underlying 
leads, and the pocket floor of the implantable pulse gen-
erator that had excess lead coils was notable for soft tissue 
inflammation. Similarly, the tissue was very friable and bled 
easily with manipulation. Interestingly, there was no fibrotic 
tissue deposition surrounding the leads, anchors, or the floor 
of the implantable pulse generator pocket. Normal wound 
healing then proceeded with an uneventful recovery.
Case 3
The patient was a 40-year-old right-handed female, who 
presented to the pain center with a diagnosis of complex 
regional pain syndrome affecting the right upper extremity. 
This condition was believed to be the result of two right 
shoulder operations for supraspinatus tendon tears. The pain 
was burning diffusely across her right shoulder, extending 
over her scapula and down her arm into her hand, with an 
intensity of 7/10. Her past history was significant only for 
asthma and sinus infections. She was allergic to nickel, 
oxycodone/acetaminophen, metronidazole, scopolamine, 
and tramadol. After multiple interventions including stel-
late and interscalene blocks, transcutaneous electrical nerve 
stimulation, physical therapy, intravenous lidocaine, and 
multimodal pharmacotherapy failed to bring appreciable 
relief, she underwent a one-week trial of SCS. After reporting 
a greater than 50% pain intensity reduction, she had a fully 
implanted dual 8 contact system placed via an upper back 
incision at the T2/3 level, with the implantable EON pulse 
generator placed in the right buttock region. A small pocket 
for lead extensions was made on the right flank just below 
the bra line at the T9 level.
The patient was seen one week after implantation and all 
wounds were healing well. She had reported some clear drain-
age from the upper back wound, but there was none noted on 
examination. Her white blood cell count was within normal 
range and she was afebrile. Five weeks later she called to say 
that she was developing a partially opened wound at the lead 
insertion site as well as the lead extension site, with copious 
amounts of clear drainage. She remained afebrile without 
chills, and denied a history of trauma or falls. Examination 
of the wound revealed minimal erythema with no hardware 
exposure but it had grossly evident soft tissue inflammation. 
Her white blood cell count was 8.7 but she had an erythrocyte 
sedimentation rate of 53 and a C-reactive protein of 11.8. 
Because of persistent wound inflammation and intermit-
tent clear drainage, the leads, silastic anchors (associated 
0 Ethibond sutures, Ethicon Inc), and lead extensions were 
removed 7 weeks post implantation. The clinical plan was 
to reinsert the leads at a lower level if it was proven to be 
less immunoreactive using the methods described in case 1. 
Figure 6A and B displays the histology of the specimen 
results sent from the upper back wound. The wounds healed 
rapidly with removal of the leads and anchors.
One month after removal of the leads, the patient called 
to report a minor amount of bleeding from the buttock wound 
where the implantable pulse generator had been implanted. 
She reported no falls or trauma. On examination, the buttock 
wound had progressed to early dehiscence with clear drainage. 
She was afebrile and her white blood cell count was 8.1, 
erythrocyte sedimentation rate was 45, and C-reactive protein 
A
Figure 5 (A) Histopathologic examination of skin and soft tissue specimen taken 
from the mid back (Figure 4), showing skin and subcutaneous tissue with ulceration 
and necrosis, acute and chronic inflammation, and a foreign body multinucleated 
giant cell reaction. (B) Arrow points to one of the many multinucleated giant cells 
seen close up from tissue detailed in (A).
B
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was 13.8. The implantable pulse generator was subsequently 
removed at approximately 11 weeks post implantation. An 
inflammatory reaction of the pocket floor was noted with 
very friable tissue (Figure 7). The fibrous floor of the pocket 
that is usually well formed at 3 months post-implantation was 
disrupted by inflammation. There were no signs of purulence 
or infection. A week later, all her wounds were healing well 
and the drainage had ceased from the buttock.
Discussion
Allergic or other inflammatory reactions to the components 
of spinal cord stimulation systems have only rarely been 
reported.6–8 A search of the literature revealed only one 
recent detailed case series to our knowledge, ie, a report 
from France describing two cases of cutaneous eruption 
related to spinal cord stimulators.6 The first of these cases 
was a foreign body type reaction to the silicone component 
of the   neurostimulatory electrodes, with histology of the 
affected tissue showing a foreign body granuloma forma-
tion. A similar foreign body granuloma reaction occurred 
after device removal at the surgical scar, in response to 
silicone particles. The second case was that of a contact 
dermatitis reaction thought to be due to the silicone part of 
the stimulator, with histology of affected tissue showing a 
contact dermatitis pattern. Delayed hypersensitivity patch 
testing confirmed a specific sensitivity to silicone.
While reports of inflammatory reactions to spinal cord 
stimulator devices are exceedingly rare, reactions to other 
devices, such as pacemakers and cardiac defibrillators, 
have been reported less rarely.9 The apparent higher rate 
of inflammatory reaction to cardiac rhythm management 
devices compared with SCS may in part relate to the fact 
that the former has a higher implantation rate. Two types of 
delayed inflammatory responses might occur in response to 
implanted devices, ie, delayed hypersensitivity responses 
to a specific antigen (eg, the metal polyurethane or silicone 
rubber of a device) or foreign body giant cell granuloma 
reactions to device material(s). Delayed hypersensitiv-
ity responses to an allergen are mediated by T cells and 
monocytes/macrophages, rather than antibodies. Contact 
dermatitis is a form of delayed hypersensitivity reaction 
to antigen at the surface of the skin, but a similar process 
can occur to substances inoculated intradermally or sub-
dermally. The patient in case 1 developed such a reaction 
likely to the polyurethane lead extensions because the rash 
was along the entire length of their course. This rash was 
treated successfully with topical hydrocortisone, but the 
patient presented within 2 weeks with wound dehiscence 
A
Figure 6 (A) Histopathology results for a specimen taken from the T2/3 level of 
the back (lead insertion wound). Microscopic analysis reveals granulation tissue with 
hemorrhage, acute and chronic inflammation, and a focal foreign body giant cell 
reaction. (B) Arrow points to multinucleated giant cell seen close up from tissue 
detailed in (A).
B Figure 7 Open wound of the right buttock with implantable pulse generator. The 
floor of the pocket has modest fibrous tissue with a collection of friable reactive 
tissue.
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predisposing to early infection as suggested by the cultures 
and inflammatory histology. We suspect that the proximity 
of hydrocortisone treatment to the healing wounds coupled 
with an inflammatory reaction likely reduced the tensile 
strength, leading to dehiscence. While contact dermatitis 
presented approximately one month after implantation, it 
may present as soon as 8 days, as recently reported after 
implantation of a peripheral nerve stimulator.10
For contact dermatitis (delayed hypersensitivity reac-
tions to items on the surface of the skin), patch testing is 
a diagnostic technique that can be utilized. This involves 
placing a suspected substance on the surface of the skin for 
48 hours, then looking for an inflammatory response of the 
skin at 48–96 hours. While this technique can be helpful in 
some cases, even with contact dermatitis, there can be false 
negatives and false positives. There is little known about 
whether patch testing can predict responses to a device that 
is implanted subcutaneously. The immune system response 
that occurs with absorption of an allergen from the surface 
of the skin through the epidermis can be different from that 
which occurs when the same substance is implanted. The 
literature provides little insight on the reliability of patch test-
ing to predict an inflammatory response to implanted devices. 
Because of the authors’ prior experience of false negatives 
on skin patch testing and the aforementioned complications 
of case 1, it was thought necessary to try an “in vivo” test 
of a piece of lead extension in another site for placement of 
the implantable pulse generator (Figure 3). Interestingly, this 
2-month test of implantation of the lead extension fragment in 
the buttock region did not result in any reaction, and the device 
was successfully implanted. We are unable to explain why 
an inflammatory dermatitis occurred in the flank/abdominal 
region but was absent in the back and buttock area.
In addition to contact dermatitis, a delayed hypersensitiv-
ity reaction may manifest as a granuloma, as reported in the 
French case series. With delayed hypersensitivity reactions, 
an antigen is taken up by macrophages or monocytes and is 
then presented to T cells which can specifically recognize that 
antigen (ie, there is memory from previous exposure to the 
antigen). This leads to recruitment of further inflammatory 
cells to the area, including macrophages that can in turn 
form giant cells. Overall, this inflammatory pattern involv-
ing T cells and macrophages is referred to as a granuloma.
A foreign body reaction can invoke a similar inflamma-
tory pattern, but it is not in response to a particular immuno-
logically recognized antigen. The inflammatory reaction in 
response to a foreign body starts as the body tries to respond 
to the foreign substance by attempting to clean the substance 
out from the body. Neutrophils and macrophages attempt to 
phagocytose the foreign substance. Macrophages will remain 
at the foreign body site for an extended period of time, and 
recruit other inflammatory cells to the area via secretion of 
chemokines. Granulation tissue can form at the site of the 
foreign body reaction (similar to granulation tissue seen with 
wound healing, but in a foreign body reaction, the healing pro-
cess is unable to complete itself). Therefore, the foreign body 
reaction consists of persistent inflammation, characterized by 
foreign body giant cells and granulomas seen on histology. 
Foreign body giant cells form when macrophages encounter 
a large foreign body (such as the components of an SCS 
implant). Because the macrophage cells cannot phagocytose 
the foreign body, the cells fuse together to form a “giant cell” 
composed of many fused macrophages. In this case series, 
the histology of the affected tissue from cases 2 and 3 was 
that of a foreign body giant cell reaction (Figure 5A and B, 
and Figure 6A and B). In case 2, the clinical impression is 
that the polyurethane leads are the likely allergens, given that 
the inflammatory response was seen in the implantable pulse 
generator pocket floor where the excess lead coils are placed. 
However, the silicone anchors cannot be excluded. Regarding 
case 3, the polyurethane-coated leads and extensions are 
even more likely to be the offending stimulus, given that the 
reaction was in all three wounds, including lead insertion, 
lead extension, and implantable pulse generator. Component 
materials, which include silicone rubber (eg, anchors), poly-
urethane (leads, extensions), titanium (implantable pulse 
generator), and platinum/iridium (electrodes), are part of an 
“allergy test kit” (St Jude Medical Neuromodulation) and can 
be applied topically as a skin patch test.11 Among the current 
three vendors, materials used for the components of SCS 
devices are similar on account of regulation by the US Food 
and Drug Administration. No further skin patch or “in vivo” 
testing was pursued because, given the location of the inflam-
matory reaction, it was not felt that allergy testing would alter 
future clinical decision-making in cases 2 and 3. All patients 
who receive an implanted device develop some degree of 
foreign body reaction around the device. Why some patients 
but not others develop a substantial, pathologic, and clinically 
detrimental level of reaction is not fully known.12,13 Interest-
ingly, none of the three patients in this case series had a history 
of prior allergies to metal, rubber, or autonomic dysfunction 
to suggest predisposition to cutaneous reactions.
Conclusion
In summary, delayed inflammatory responses to the 
components of SCS devices can manifest via T cell/
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monocyte-mediated delayed hypersensitivity reactions or 
foreign body giant cell reactions. Contact dermatitis, granu-
loma formation, and foreign body reactions with giant cell 
formation are possible in response to SCS devices. The role 
of skin patch testing remains uncertain when testing for for-
eign body reactions because these occurred one month after 
implantation. While the lead/extension polyurethane compo-
nent is suspected as the most immunogenic source in this case 
series, other materials of the SCS device cannot be excluded. 
Excision of the inflamed tissue and histologic evaluation is 
the key for diagnosis and distinguishing between infection 
and inflammation. Infection may occur as a complication of 
poor wound healing because of an underlying inflammatory 
response to the component(s) of the SCS device.
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